| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1036039977 |
| P356 | DOI | 10.1007/S00482-010-0940-0 |
| P953 | full work available at URL | http://link.springer.com/article/10.1007/s00482-010-0940-0/fulltext.html |
| http://link.springer.com/content/pdf/10.1007/s00482-010-0940-0.pdf | ||
| http://link.springer.com/content/pdf/10.1007/s00482-010-0940-0 | ||
| P698 | PubMed publication ID | 20882301 |
| P2093 | author name string | B. Alt-Epping | |
| F. Nauck | |||
| P2860 | cites work | Lapatinib plus capecitabine for HER2-positive advanced breast cancer | Q27851403 |
| New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) | Q28131668 | ||
| Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer | Q28278736 | ||
| Erlotinib in previously treated non-small-cell lung cancer | Q29547546 | ||
| Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial | Q29547565 | ||
| Screening for epidermal growth factor receptor mutations in lung cancer | Q29619696 | ||
| Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study. | Q33386298 | ||
| Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. | Q34579127 | ||
| Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology | Q37103057 | ||
| Aggressiveness of cancer care near the end of life: is it a quality-of-care issue? | Q37126136 | ||
| Clinical benefit in oncology trials: is this a patient-centred or tumour-centred end-point? | Q37527312 | ||
| Treatment outcome in performance status 2 advanced NSCLC patients administered platinum-based combination chemotherapy. | Q39320952 | ||
| We should desist using RECIST, at least in GIST. | Q40217664 | ||
| Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM). | Q42927824 | ||
| Second-line treatments of advanced non-small-cell lung cancer: new evidence for clinical practice | Q43240277 | ||
| Association between incremental gains in the objective response rate and survival improvement in phase III trials of first-line chemotherapy for extensive disease small-cell lung cancer | Q43911887 | ||
| Should screening for DPD deficiency be mandatory before 5-FU exposure? | Q45189579 | ||
| Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. | Q46232500 | ||
| Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients | Q46546767 | ||
| Small molecule inhibitors of tyrosine kinase: waiting for the good news in colorectal cancer as well | Q46581102 | ||
| A pilot study of docetaxel and trofosfamide as second-line 'metronomic' chemotherapy in the treatment of metastatic non-small cell lung cancer (NSCLC). | Q46640553 | ||
| A phase II clinical trial of sorafenib in androgen-independent prostate cancer | Q46825505 | ||
| Extensive-stage small-cell lung cancer--moving beyond response rate? | Q57569694 | ||
| Quality of Life and Pain in Advanced Stage Prostate Cancer: Results of a Southwest Oncology Group Randomized Trial Comparing Docetaxel and Estramustine to Mitoxantrone and Prednisone | Q59575102 | ||
| Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis | Q59901778 | ||
| Analgesic effects of chemotherapy? | Q60678674 | ||
| Clinical benefit as a primary efficacy endpoint | Q74195597 | ||
| Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21 | Q80142699 | ||
| Circulating tumor cells in metastatic breast cancer--toward individualized treatment? | Q80468058 | ||
| Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer | Q80970864 | ||
| Antiangiogenic metronomic chemotherapy | Q81099924 | ||
| [Evaluating treatment from the point of view of the patient -PROs (patient-reported outcomes)] | Q84060579 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | German | Q188 |
| P304 | page(s) | 633-641 | |
| P577 | publication date | 2010-12-01 | |
| P1433 | published in | Der Schmerz | Q2413522 |
| P478 | volume | 24 |
| Q87649974 | [Pain therapy in oncology: results of a nationwide survey] | cites work | P2860 |
Search more.